BIG Faculty Member - Kimberly Stegmaier, M.D.

Kimberly Stegmaier, M.D.

Associate Professor, Pediatrics, Harvard Medical School
Attending Physician, Pediatric Oncology, Boston Children's Hospital
Principal Investigator, Pediatric Oncology, Dana-Farber Cancer Institute
Co-Director, Pediatric Hematologic Malignancy Program, Boston Children's Hospital and Dana-Farber Cancer Institute

Dana Farber Cancer Institute
450 Brookline Ave
Dana 360D
Boston, MA 02215
Email: Kimberly_Stegmaier@dfci.harvard.edu
Visit my lab page here and here.



My research program focuses on the integration of “omic” approaches for the identification of new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. Cancer discovery efforts in my laboratory have focused on the alteration of the malignant state (e.g., AML and neuroblastoma differentiation) and the modulation of pharmacologically challenging oncoproteins (e.g., EWS/FLI in Ewing sarcoma, MYCN in neuroblastoma, and NOTCH1 in T-ALL.) Most recently, we are applying an integrated approach to discover new therapeutic opportunities in these malignancies with deep genomic characterization of primary tumors, kinase activity profiling for immediately druggable targets, functional genomic screening for new tumor dependencies and chemical screening for modulators of relevant oncogenic drivers. Clinical trials for patients with AML and Ewing sarcoma have resulted from our research and a trial testing BET bromodomain inhibitors in patients with MYCN amplified neuroblastoma is in development.



Last Update: 11/27/2017



Publications



© 2016 President and Fellows
of Harvard College